Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis.

Date publication

janvier 2015

Journal

European neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry

Tous les auteurs :
Magnin E, Sagawa Y, Chamard L, Berger E, Moulin T, Decavel P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26624899

Résumé

Fampridine is sometimes reported to improve cognition and especially the information-processing speed. Motor improvement might be a confounding factor. The aim of this study was to evaluate the effects of fampridine on verbal fluencies in patients with multiple sclerosis (MS).

Mots clés

4-Aminopyridine, therapeutic use, Adult, Cognition Disorders, drug therapy, Disability Evaluation, Female, France, Gait Apraxia, drug therapy, Humans, Male, Middle Aged, Multiple Sclerosis, drug therapy, Prospective Studies, Speech Disorders, drug therapy, Speech Production Measurement, Verbal Behavior, drug effects

Référence

Eur Neurol. 2015 ;74(5-6):243-50